Given the small number of ε4/ε4 carriers in this sample, future research is needed to evaluate the effectiveness of PCSK9 inhibitors to reduce the risk of cognitive decline in those most at risk for Alzheimer’s disease. The gene discussed is PCSK9; the disease is Alzheimer disease.